{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T13:16:28Z","timestamp":1792588588761,"version":"4.5.0"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,6,22]],"date-time":"2018-06-22T00:00:00Z","timestamp":1529625600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2018,6,22]],"date-time":"2018-06-22T00:00:00Z","timestamp":1529625600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100006041","name":"Innovate UK","doi-asserted-by":"publisher","award":["972216"],"award-info":[{"award-number":["972216"]}],"id":[{"id":"10.13039\/501100006041","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Zika virus (ZIKV) emerged on a global scale and no licensed vaccine ensures long-lasting anti-ZIKV immunity. Here we report the design and comparative evaluation of four replication-deficient chimpanzee adenoviral (ChAdOx1) ZIKV vaccine candidates comprising the addition or deletion of precursor membrane (prM) and envelope, with or without its transmembrane domain (TM). A single, non-adjuvanted vaccination of ChAdOx1 ZIKV vaccines elicits suitable levels of protective responses in mice challenged with ZIKV. ChAdOx1 prME \u2206TM encoding prM and envelope without TM provides 100% protection, as well as long-lasting anti-envelope immune responses and no evidence of in vitro antibody-dependent enhancement to dengue virus. Deletion of prM and addition of TM reduces protective efficacy and yields lower anti-envelope responses. Our finding that immunity against ZIKV can be enhanced by modulating antigen membrane anchoring highlights important parameters in the design of viral vectored ZIKV vaccines to support further clinical assessments.<\/jats:p>","DOI":"10.1038\/s41467-018-04859-5","type":"journal-article","created":{"date-parts":[[2018,6,18]],"date-time":"2018-06-18T11:35:38Z","timestamp":1529321738000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":84,"title":["Rational Zika vaccine design via the modulation of antigen membrane anchors in chimpanzee adenoviral vectors"],"prefix":"10.1038","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7932-2341","authenticated-orcid":false,"given":"C\u00e9sar","family":"L\u00f3pez-Camacho","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1978-088X","authenticated-orcid":false,"given":"Peter","family":"Abbink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9995-1804","authenticated-orcid":false,"given":"Rafael A.","family":"Larocca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wanwisa","family":"Dejnirattisai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Boyd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex","family":"Badamchi-Zadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zo\u00eb R.","family":"Wallace","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Doig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6716-442X","authenticated-orcid":false,"given":"Ricardo Sanchez","family":"Velazquez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3983-8025","authenticated-orcid":false,"given":"Roberto Dias Lins","family":"Neto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1111-0825","authenticated-orcid":false,"given":"Danilo F.","family":"Coelho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2847-9407","authenticated-orcid":false,"given":"Young Chan","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4370-0707","authenticated-orcid":false,"given":"Claire L.","family":"Donald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ania","family":"Owsianka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuditta","family":"De Lorenzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alain","family":"Kohl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6823-9750","authenticated-orcid":false,"given":"Sarah C.","family":"Gilbert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucy","family":"Dorrell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juthathip","family":"Mongkolsapaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4600-2047","authenticated-orcid":false,"given":"Arvind H.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gavin R.","family":"Screaton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan H.","family":"Barouch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0900-9629","authenticated-orcid":false,"given":"Adrian V. S.","family":"Hill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2648-1696","authenticated-orcid":false,"given":"Arturo","family":"Reyes-Sandoval","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,6,22]]},"reference":[{"key":"4859_CR1","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1016\/0035-9203(52)90042-4","volume":"46","author":"GW Dick","year":"1952","unstructured":"Dick, G. W., Kitchen, S. F. & Haddow, A. J. Zika virus. I. Isolations and serological specificity. Trans. R. Soc. Trop. Med. Hyg. 46, 509\u2013520 (1952).","journal-title":"Trans. R. Soc. Trop. Med. Hyg."},{"key":"4859_CR2","doi-asserted-by":"publisher","first-page":"20720","DOI":"10.2807\/1560-7917.ES2014.19.9.20720","volume":"19","author":"E Oehler","year":"2014","unstructured":"Oehler, E. et al. Zika virus infection complicated by Guillain-Barre syndrome\u2014case report, French Polynesia, December 2013. Eur. Surveill. 19, 20720 (2014).","journal-title":"Eur. Surveill."},{"key":"4859_CR3","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/S0140-6736(16)00006-4","volume":"387","author":"CV Ventura","year":"2016","unstructured":"Ventura, C. V., Maia, M., Bravo-Filho, V., Gois, A. L. & Belfort, R. Jr. Zika virus in Brazil and macular atrophy in a child with microcephaly. Lancet 387, 228 (2016).","journal-title":"Lancet"},{"key":"4859_CR4","doi-asserted-by":"publisher","first-page":"1907","DOI":"10.1056\/NEJMc1610613","volume":"375","author":"S Swaminathan","year":"2016","unstructured":"Swaminathan, S., Schlaberg, R., Lewis, J., Hanson, K. E. & Couturier, M. R. Fatal Zika virus infection with secondary nonsexual transmission. N. Engl. J. Med. 375, 1907\u20131909 (2016).","journal-title":"N. Engl. J. Med."},{"key":"4859_CR5","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1038\/nature17994","volume":"533","author":"VA Kostyuchenko","year":"2016","unstructured":"Kostyuchenko, V. A. et al. Structure of the thermally stable Zika virus. Nature 533, 425\u2013428 (2016).","journal-title":"Nature"},{"key":"4859_CR6","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1126\/science.aaf5316","volume":"352","author":"D Sirohi","year":"2016","unstructured":"Sirohi, D. et al. The 3.8 A resolution cryo-EM structure of Zika virus. Science 352, 467\u2013470 (2016).","journal-title":"Science"},{"key":"4859_CR7","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1038\/nature18952","volume":"536","author":"RA Larocca","year":"2016","unstructured":"Larocca, R. A. et al. Vaccine protection against Zika virus from Brazil. Nature 536, 474\u2013478 (2016).","journal-title":"Nature"},{"key":"4859_CR8","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1016\/j.cell.2016.08.004","volume":"166","author":"LJ Yockey","year":"2016","unstructured":"Yockey, L. J. et al. Vaginal exposure to Zika virus during pregnancy leads to fetal brain infection. Cell 166, 1247\u20131256.e4 (2016).","journal-title":"Cell"},{"key":"4859_CR9","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1126\/science.aah6157","volume":"353","author":"P Abbink","year":"2016","unstructured":"Abbink, P. et al. Protective efficacy of multiple vaccine platforms against Zika virus challenge in rhesus monkeys. Science 353, 1129\u20131132 (2016).","journal-title":"Science"},{"key":"4859_CR10","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1126\/science.aai9137","volume":"354","author":"KA Dowd","year":"2016","unstructured":"Dowd, K. A. et al. Rapid development of a DNA vaccine for Zika virus. Science 354, 237\u2013240 (2016).","journal-title":"Science"},{"key":"4859_CR11","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-00193-w","volume":"7","author":"JS Chahal","year":"2017","unstructured":"Chahal, J. S. et al. An RNA nanoparticle vaccine against Zika virus elicits antibody and CD8+T cell responses in a mouse model. Sci. Rep. 7, 252 (2017).","journal-title":"Sci. Rep."},{"key":"4859_CR12","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1038\/nri.2017.132","volume":"18","author":"MS Diamond","year":"2018","unstructured":"Diamond, M. S. & Coyne, C. B. Vaccines in 2017: closing in on a Zika virus vaccine. Nat. Rev. Immunol. 18, 89\u201390 (2018).","journal-title":"Nat. Rev. Immunol."},{"key":"4859_CR13","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1038\/nature21428","volume":"543","author":"N Pardi","year":"2017","unstructured":"Pardi, N. et al. Zika virus protection by a single low-dose nucleoside-modified mRNA vaccination. Nature 543, 248\u2013251 (2017).","journal-title":"Nature"},{"key":"4859_CR14","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-03662-6","volume":"9","author":"NA Prow","year":"2018","unstructured":"Prow, N. A. et al. A vaccinia-based single vector construct multi-pathogen vaccine protects against both Zika and chikungunya viruses. Nat. Commun. 9, 1230 (2018).","journal-title":"Nat. Commun."},{"key":"4859_CR15","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/j.cell.2017.03.016","volume":"169","author":"JM Richner","year":"2017","unstructured":"Richner, J. M. et al. Modified mRNA vaccines protect against Zika virus infection. Cell 169, 176 (2017).","journal-title":"Cell"},{"key":"4859_CR16","doi-asserted-by":"publisher","first-page":"eaao4163","DOI":"10.1126\/scitranslmed.aao4163","volume":"9","author":"P Abbink","year":"2017","unstructured":"Abbink, P. et al. Durability and correlates of vaccine protection against Zika virus in rhesus monkeys. Sci. Transl. Med. 9, eaao4163 (2017).","journal-title":"Sci. Transl. Med."},{"key":"4859_CR17","first-page":"e01722","volume":"92","author":"K Xu","year":"2018","unstructured":"Xu, K. et al. Recombinant chimpanzee adenovirus vaccine AdC7-M\/E protects against Zika virus infection and testis damage. J. Virol. 92, e01722\u201317 (2018).","journal-title":"J. Virol."},{"key":"4859_CR18","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.ebiom.2017.10.006","volume":"25","author":"G Yi","year":"2017","unstructured":"Yi, G. et al. A DNA vaccine protects human immune cells against Zika virus infection in humanized mice. EBioMedicine 25, 87\u201394 (2017).","journal-title":"EBioMedicine"},{"key":"4859_CR19","doi-asserted-by":"publisher","first-page":"73","DOI":"10.4269\/ajtmh.2012.12-0361","volume":"88","author":"SJ Thomas","year":"2013","unstructured":"Thomas, S. J. et al. A phase II, randomized, safety and immunogenicity study of a re-derived, live-attenuated dengue virus vaccine in healthy adults. Am. J. Trop. Med. Hyg. 88, 73\u201388 (2013).","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"4859_CR20","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1016\/S0140-6736(17)33106-9","volume":"391","author":"K Modjarrad","year":"2017","unstructured":"Modjarrad, K. et al. Preliminary aggregate safety and immunogenicity results from three trials of a purified inactivated Zika virus vaccine candidate: phase 1, randomised, double-blind, placebo-controlled clinical trials. Lancet 391, 563\u2013571 (2017).","journal-title":"Lancet"},{"key":"4859_CR21","doi-asserted-by":"publisher","first-page":"e0005048","DOI":"10.1371\/journal.pntd.0005048","volume":"10","author":"CL Donald","year":"2016","unstructured":"Donald, C. L. et al. Full genome sequence and sfRNA interferon antagonist activity of Zika virus from Recife, Brazil. PLoS Negl. Trop. Dis. 10, e0005048 (2016).","journal-title":"PLoS Negl. Trop. Dis."},{"key":"4859_CR22","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1038\/ni.3515","volume":"17","author":"W Dejnirattisai","year":"2016","unstructured":"Dejnirattisai, W. et al. Dengue virus sero-cross-reactivity drives antibody-dependent enhancement of infection with zika virus. Nat. Immunol. 17, 1102\u20131108 (2016).","journal-title":"Nat. Immunol."},{"key":"4859_CR23","doi-asserted-by":"publisher","first-page":"7100","DOI":"10.1016\/j.vaccine.2015.09.108","volume":"33","author":"B Guy","year":"2015","unstructured":"Guy, B., Briand, O., Lang, J., Saville, M. & Jackson, N. Development of the Sanofi Pasteur tetravalent dengue vaccine: one more step forward. Vaccine 33, 7100\u20137111 (2015).","journal-title":"Vaccine"},{"key":"4859_CR24","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1056\/NEJMoa1411037","volume":"372","author":"L Villar","year":"2015","unstructured":"Villar, L. et al. Efficacy of a tetravalent dengue vaccine in children in Latin America. N. Engl. J. Med. 372, 113\u2013123 (2015).","journal-title":"N. Engl. J. Med."},{"key":"4859_CR25","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/j.ebiom.2016.09.028","volume":"13","author":"E Kim","year":"2016","unstructured":"Kim, E. et al. Preventative vaccines for Zika virus outbreak: preliminary evaluation. EBioMedicine 13, 315\u2013320 (2016).","journal-title":"EBioMedicine"},{"key":"4859_CR26","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1006\/prep.1998.0926","volume":"14","author":"A Golden","year":"1998","unstructured":"Golden, A. et al. Effect of promoters and signal sequences on the production of secreted HIV-1 gp120 protein in the baculovirus system. Protein Expr. Purif. 14, 8\u201312 (1998).","journal-title":"Protein Expr. Purif."},{"key":"4859_CR27","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.jviromet.2008.08.011","volume":"154","author":"M Luo","year":"2008","unstructured":"Luo, M. et al. Immunization with plasmid DNA encoding influenza A virus nucleoprotein fused to a tissue plasminogen activator signal sequence elicits strong immune responses and protection against H5N1 challenge in mice. J. Virol. Methods 154, 121\u2013127 (2008).","journal-title":"J. Virol. Methods"},{"key":"4859_CR28","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1016\/S0140-6736(13)60177-4","volume":"381","author":"MD Tameris","year":"2013","unstructured":"Tameris, M. D. et al. Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo-controlled phase 2b trial. Lancet 381, 1021\u20131028 (2013).","journal-title":"Lancet"},{"key":"4859_CR29","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1016\/S1473-3099(14)70845-X","volume":"14","author":"I Satti","year":"2014","unstructured":"Satti, I. et al. Safety and immunogenicity of a candidate tuberculosis vaccine MVA85A delivered by aerosol in BCG-vaccinated healthy adults: a phase 1, double-blind, randomised controlled trial. Lancet Infect. Dis. 14, 939\u2013946 (2014).","journal-title":"Lancet Infect. Dis."},{"key":"4859_CR30","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1016\/S0140-6736(17)33105-7","volume":"391","author":"MR Gaudinski","year":"2017","unstructured":"Gaudinski, M. R. et al. Safety, tolerability, and immunogenicity of two Zika virus DNA vaccine candidates in healthy adults: randomised, open-label, phase 1 clinical trials. Lancet 391, 552\u2013562 (2017).","journal-title":"Lancet"},{"key":"4859_CR31","doi-asserted-by":"publisher","unstructured":"Tebas, P. et al. Safety and immunogenicity of an anti-Zika virus DNA vaccine\u2014preliminary report. N. Engl. J. Med. https:\/\/doi.org\/10.1056\/NEJMoa1708120 (2017).","DOI":"10.1056\/NEJMoa1708120"},{"key":"4859_CR32","doi-asserted-by":"publisher","unstructured":"Halstead, S. B. Dengue antibody-dependent enhancement: knowns and unknowns. Microbiol. Spectr. 2 https:\/\/doi.org\/10.1128\/microbiolspec.AID-0022-2014 (2014).","DOI":"10.1128\/microbiolspec.AID-0022-2014"},{"key":"4859_CR33","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1016\/S1473-3099(10)70166-3","volume":"10","author":"SB Halstead","year":"2010","unstructured":"Halstead, S. B., Mahalingam, S., Marovich, M. A., Ubol, S. & Mosser, D. M. Intrinsic antibody-dependent enhancement of microbial infection in macrophages: disease regulation by immune complexes. Lancet Infect. Dis. 10, 712\u2013722 (2010).","journal-title":"Lancet Infect. Dis."},{"key":"4859_CR34","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms15674","volume":"8","author":"P Pantoja","year":"2017","unstructured":"Pantoja, P. et al. Zika virus pathogenesis in rhesus macaques is unaffected by pre-existing immunity to dengue virus. Nat. Commun. 8, 15674 (2017).","journal-title":"Nat. Commun."},{"key":"4859_CR35","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1126\/science.aaf8505","volume":"353","author":"K Stettler","year":"2016","unstructured":"Stettler, K. et al. Specificity, cross-reactivity, and function of antibodies elicited by Zika virus infection. Science 353, 823\u2013826 (2016).","journal-title":"Science"},{"key":"4859_CR36","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1038\/mt.2013.284","volume":"22","author":"RD Antrobus","year":"2014","unstructured":"Antrobus, R. D. et al. Clinical assessment of a novel recombinant simian adenovirus ChAdOx1 as a vectored vaccine expressing conserved Influenza A antigens. Mol. Ther. 22, 668\u2013674 (2014).","journal-title":"Mol. Ther."},{"key":"4859_CR37","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1038\/mt.2013.248","volume":"22","author":"N Borthwick","year":"2014","unstructured":"Borthwick, N. et al. Vaccine-elicited human T cells recognizing conserved protein regions inhibit HIV-1. Mol. Ther. 22, 464\u2013475 (2014).","journal-title":"Mol. Ther."},{"key":"4859_CR38","doi-asserted-by":"publisher","first-page":"1635","DOI":"10.1056\/NEJMoa1411627","volume":"374","author":"K Ewer","year":"2016","unstructured":"Ewer, K. et al. A monovalent chimpanzee adenovirus ebola vaccine boosted with MVA. N. Engl. J. Med. 374, 1635\u20131646 (2016).","journal-title":"N. Engl. J. Med."},{"key":"4859_CR39","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms3836","volume":"4","author":"KJ Ewer","year":"2013","unstructured":"Ewer, K. J. et al. Protective CD8+T cell immunity to human malaria induced by chimpanzee adenovirus-MVA immunisation. Nat. Commun. 4, 2836 (2013).","journal-title":"Nat. Commun."},{"key":"4859_CR40","doi-asserted-by":"publisher","first-page":"300ra126","DOI":"10.1126\/scitranslmed.aac5745","volume":"7","author":"CA Green","year":"2015","unstructured":"Green, C. A. et al. Chimpanzee adenovirus- and MVA-vectored respiratory syncytial virus vaccine is safe and immunogenic in adults. Sci. Transl. Med. 7, 300ra126 (2015).","journal-title":"Sci. Transl. Med."},{"key":"4859_CR41","doi-asserted-by":"publisher","first-page":"e0003947","DOI":"10.1371\/journal.pntd.0003947","volume":"9","author":"M Poggianella","year":"2015","unstructured":"Poggianella, M. et al. Dengue E protein domain III-based DNA immunisation induces strong antibody responses to all four viral serotypes. PLoS Negl. Trop. Dis. 9, e0003947 (2015).","journal-title":"PLoS Negl. Trop. Dis."},{"key":"4859_CR42","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1038\/nature18938","volume":"536","author":"G Barba-Spaeth","year":"2016","unstructured":"Barba-Spaeth, G. et al. Structural basis of potent Zika-dengue virus antibody cross-neutralization. Nature 536, 48\u201353 (2016).","journal-title":"Nature"}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-018-04859-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-018-04859-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-018-04859-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,20]],"date-time":"2022-12-20T14:47:33Z","timestamp":1671547653000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-018-04859-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6,22]]},"references-count":42,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2018,12]]}},"alternative-id":["4859"],"URL":"https:\/\/doi.org\/10.1038\/s41467-018-04859-5","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,6,22]]},"assertion":[{"value":"11 January 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 May 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 June 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A.R.-S. and C.L.-C. are co-inventors of the Zika vaccines described in this manuscript, filed by Oxford University Innovation Limited in the International Patent Application No. PCT\/GB2017\/052220 Zika Vaccine; A.V.S.H. and S.C.G. are co-inventors on a patent application (WO\/2012\/172277) on the ChAdOx1 viral vector filed by Oxford University Innovation. The remaining authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"2441"}}